Jefferies Sees Hemlibra-Like Potential in Hemab Therapeutics, Starts Coverage with Buy Rating
Hemab targets rare bleeding diseases with new treatments, strong cash, and big growth potential, with analysts seeing ~50% upside.
/ 79 items
#XY Analyst Up/Down↓
Tectonic Therapeutics Gets Strong Buy Upgrade: Two Potential Blockbusters in Focus
Raymond James upgraded Tectonic Therapeutics to Strong Buy and raised its price target to $81. Analyst highlights the potential of TX45 and TX2100 as two blockbuster candidates at a low valuation.
Mizuho Turns Positive on Q32 Bio’s Bempikibart, Initiates Coverage with Outperform Rating
Mizuho sees Q32 Bio upside with $14 target vs ~$5.50, boosted by bempikibart alopecia drug progress and 2026 data.
Wall Street Turns Cautious on Summit Therapeutics: Bernstein Slaps Underperform Rating, Predicts Phase 3 Failures
Analysts warn Summit may fail key trials, lacks revenue, and faces pressure—raising doubts about its future and stock upside.
Wall Street Upgrades Two Biotech Stocks: STRO Price Target Tripled, ORIC Now a Buy
Wedbush lifts Sutro to $60 on STRO-004 hopes; ORIC upgraded on strong cancer data and big market potential.
UBS Turns Bullish on CORT: Lifyorli Expected to Beat Expectations
UBS upgraded CORT to Buy, raised target to $72 on strong Lifyorli cancer drug outlook and steady Korlym sales. Upside ~60–70%.